What is KYTX (KYTX) stock price today?

KYTX (KYTX) is currently trading at $8.62, up 3.17% today.

What is KYTX P/E ratio?

KYTX's P/E ratio is -2.85. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is KYTX return on equity (ROE)?

KYTX's return on equity (ROE) is -81.91%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is KYTX's market cap?

KYTX has a market capitalization of $523.75M.

NASDAQ · Biotechnology

KYTX (KYTX) Stock

$8.62 +3.17% NASDAQ: KYTX Healthcare

Valuation

Metric	Value
Price	$8.62
Market Cap	$523.75M
P/E Ratio	-2.85
P/B Ratio	3.08
P/S Ratio	0.00
EPS (TTM)	$-3.64
52-Week High	$13.67
52-Week Low	$3.55
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-81.91%
ROA	-69.44%
ROCE	-80.67%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.20
Current Ratio	7.86

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$6.0M	$7.0M	$0	$0	$0
Operating Profit	$-26.0M	$-29.0M	$-62.0M	$-143.0M	$-170.0M
Net Profit	$-26.0M	$-29.0M	$-60.0M	$-127.0M	$-161.0M
EPS	$-1.02	$-1.12	$0.00	$-3.33	$-3.64
Op Margin	-465.8%	-418.3%	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$85.0M	$67.0M	$75.0M	$305.0M	$294.0M
Total Liabilities	$132.0M	$141.0M	$26.0M	$38.0M	$62.0M
Cash	$76.0M	$38.0M	$35.0M	$97.0M	$124.0M
Borrowings	$6.0M	$11.0M	$9.0M	$8.0M	$29.0M

Latest News

Kyverna Therapeutics Sinks 13%: Here’s Why 24/7 Wall St. · Jul 10, 2026 Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond Insider Monkey · Jul 9, 2026 Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition GlobeNewswire · Jun 22, 2026 FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases Exec Edge · Jun 9, 2026 Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? Motley Fool · Jun 8, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-22.0M	$-36.0M	$-52.0M	$-114.0M	$-154.0M
Investing Cash Flow	$-3.0M	$-15.0M	$-9.0M	$-163.0M	$40.0M
Financing Cash Flow	$0	$0	$-2.0M	$-3.0M	$0
Net Cash Flow	$49.0M	$-38.0M	$-3.0M	$62.0M	$27.0M
Free Cash Flow	$-23.0M	$-37.0M	$-53.0M	$-116.0M	$-154.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.13
EV / EBITDA	-3.36
FCF Yield	-31.33%
Quick Ratio	9.06
Interest Coverage	-88.69
Return 1Y	68.36%
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held7.10%

Institutions Held74.72%

Institutions Float Held80.43%

Institutional Holder	Shares	Report Date
GordonMD Global Investments LP	4,244,818	2026-03-31
Gilead Sciences Inc	4,126,119	2026-03-31
Bain Capital Life Sciences Investors, LLC	3,110,000	2026-03-31
AIGH Capital Management LLC	2,000,000	2026-03-31
Deerfield Management Company, L.P	2,000,000	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALLO	$1.98	-0.25%	-2.17	$683.41M	0.00%
AVIR	$5.70	+3.83%	-2.13	$456.15M	0.00%
CABA	$3.57	+8.18%	-2.23	$582.11M	0.00%
CAPR	$9.89	-1.20%	-4.01	$568.78M	0.00%
CTNM	$17.24	+4.17%	-6.62	$648.59M	0.00%

About KYTX

KYTX is led by CEO Warner Biddle, employs 112 people, headquartered in US, publicly traded since 2024.

KYTX stock trades at $8.62 with a market capitalization of $523.75M. The stock is valued at a price-to-earnings (P/E) ratio of -2.85, price-to-book of 3.08, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.55 and $13.67, and currently trades 36.9% below its 52-week high.

On profitability, KYTX generates a return on equity (ROE) of -81.91%, return on capital employed of -80.67%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides